Estrone
Estrogenic Substance, Theelin (estrone) is a small molecule pharmaceutical. Estrone was first approved as Theelin on 1982-01-01. It is used to treat breast neoplasms, hot flashes, hypogonadism, menorrhagia, and premature menopause amongst others in the USA. The pharmaceutical is active against estrogen receptor. In addition, it is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 1C1, solute carrier organic anion transporter family member 2B1, solute carrier organic anion transporter family member 4A1, estrogen receptor beta, solute carrier organic anion transporter family member 3A1, and solute carrier organic anion transporter family member 1B1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Estrone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| THEELIN | Parkedale Pharmaceuticals | N-003977 DISCN | 1982-01-01 | 3 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ebv/cfs plus | unapproved drug other | 2021-07-02 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CA: Natural and semisynthetic estrogens, plain
— G03CA07: Estrone
— G03CC: Estrogens, combinations with other drugs
— G03CC04: Estrone
HCPCS
Code | Description |
|---|---|
| J1435 | Injection, estrone, per 1 mg |
Clinical
Clinical Trials
735 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | HP_0000789 | — | 26 | 29 | 60 | 72 | 96 | 273 |
| Lymphoma | D008223 | — | C85.9 | 32 | 71 | 41 | 1 | 10 | 142 |
| Female infertility | D007247 | EFO_0008560 | N97 | 12 | 6 | 13 | 11 | 26 | 64 |
| Syndrome | D013577 | — | — | 11 | 17 | 6 | 7 | 24 | 61 |
| Follicular lymphoma | D008224 | — | C82 | 10 | 27 | 20 | 1 | 3 | 55 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 5 | 3 | 8 | 8 | 26 | 48 |
| Fertilization in vitro | D005307 | — | — | — | 2 | 3 | 11 | 10 | 26 |
| Neoplasms | D009369 | — | C80 | 13 | 8 | 2 | 1 | 6 | 25 |
| Ovulation induction | D010062 | — | — | 2 | 7 | 7 | 3 | 7 | 25 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 7 | 1 | 3 | 8 | 22 |
Show 45 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 25 | 18 | — | 1 | 49 |
| Leukemia | D007938 | — | C95 | 13 | 15 | 1 | — | 6 | 31 |
| Myelodysplastic syndromes | D009190 | — | D46 | 9 | 12 | 1 | — | 5 | 24 |
| Preleukemia | D011289 | — | — | 9 | 12 | 1 | — | 5 | 24 |
| Multiple myeloma | D009101 | — | C90.0 | 9 | 11 | 1 | — | 5 | 23 |
| Plasma cell neoplasms | D054219 | — | — | 8 | 11 | 1 | — | 5 | 22 |
| Plasmacytoma | D010954 | — | C90.3 | 8 | 11 | 1 | — | 5 | 22 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 8 | 9 | 1 | — | 3 | 18 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 4 | 5 | 1 | — | 10 | 17 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 2 | 1 | 1 | — | 11 | 14 |
Show 23 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 4 | 8 | — | — | 2 | 13 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 4 | 7 | — | — | 3 | 12 |
| Premature menopause | D008594 | HP_0008209 | E28.31 | 3 | 4 | — | — | 8 | 12 |
| Menopause | D008593 | EFO_0003922 | N95 | 1 | 3 | — | — | 4 | 7 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 3 | — | — | 1 | 6 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 4 | — | — | 1 | 5 |
| Recurrence | D012008 | — | — | 2 | 4 | — | — | — | 5 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 2 | — | — | 3 | 5 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 1 | 3 | — | — | 1 | 4 |
| Trophoblastic neoplasms | D014328 | — | — | 1 | 3 | — | — | 1 | 4 |
Show 49 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 4 | — | — | — | — | 4 |
| Melanoma | D008545 | — | — | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 1 | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Carcinoid tumor | D002276 | — | D3A.00 | 1 | — | — | — | — | 1 |
| Paraneoplastic syndromes | D010257 | — | — | 1 | — | — | — | — | 1 |
| Islet cell adenoma | D007516 | EFO_0007331 | D13.7 | 1 | — | — | — | — | 1 |
| Malignant carcinoid syndrome | D008303 | — | E34.0 | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menstrual cycle | D008597 | — | — | — | — | — | — | 6 | 6 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 5 | 5 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 3 | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 3 | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 3 | 3 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 2 | 2 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 2 | 2 |
| Sclerosis | D012598 | — | — | — | — | — | — | 2 | 2 |
| In vitro oocyte maturation techniques | D059471 | — | — | — | — | — | — | 2 | 2 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 2 | 2 |
Show 106 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estrone |
| INN | estrone |
| Description | Estrone is a 17-oxo steroid that is estra-1,3,5(10)-triene substituted by an hydroxy group at position 3 and an oxo group at position 17. It has a role as an estrogen, a bone density conservation agent, an antineoplastic agent, a human metabolite and a mouse metabolite. It is a 3-hydroxy steroid, a phenolic steroid, a member of phenols and a 17-oxo steroid. It derives from a hydride of an estrane. |
| Classification | Small molecule |
| Drug class | estrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O |
Identifiers
| PDB | — |
| CAS-ID | 53-16-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1405 |
| ChEBI ID | 17263 |
| PubChem CID | 5870 |
| DrugBank | DB00655 |
| UNII ID | 2DI9HA706A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ESR2
ESR2
SLCO2B1
SLCO2B1
SLCO3A1
SLCO3A1
Organism
Homo sapiens
Gene name
ESR2
Gene synonyms
ESTRB, NR3A2
NCBI Gene ID
Protein name
estrogen receptor beta
Protein synonyms
estrogen receptor beta 2, estrogen receptor beta 4, Nuclear receptor subfamily 3 group A member 2, oestrogen receptor beta
Uniprot ID
Mouse ortholog
Esr2 (13983)
estrogen receptor beta (O08537)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Estrone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,539 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
351 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use